SAR260301 / Sanofi - LARVOL DELTA

circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway. (PubMed, Sci China Life Sci) - "Notably, in vivo studies further indicated that either silencing circSCAP or co-administering the PIK3R2 inhibitor SAR-260301 with platinum significantly improves treatment efficacy in resistant TNBC models. These findings establish circSCAP and SCAP-129aa as promising biomarkers and potential therapeutic targets for overcoming platinum resistance in TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • Triple Negative Breast Cancer • PIK3R2

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. (PubMed, Cancer) - P1; "SAR260301 had an acceptable safety profile, but exposure sufficient to inhibit the PI3K pathway was unachievable because of rapid clearance, and clinical development was terminated. These results demonstrate the importance of PK and pharmacodynamic assessments in early drug development. Cancer 2017."

Clinical • Journal • P1 data